Related Experiment Video

Updated: Mar 13, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer

R Mimoto1,2, Y Imawari1,2, S Hirooka3

  • 1Department of Biochemistry, Jikei University School of Medicine, Tokyo, Japan.

Oncogene
|October 11, 2016
PubMed

Insights

Dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) regulates breast cancer stem cells. Lower DYRK2 levels enhance cancer stem cell traits and tumor growth, identifying a new therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer stem cell (CSC) theory is supported by accumulating studies.
  • A specific therapy targeting CSCs remains to be established.
  • Understanding CSC regulation is crucial for effective breast cancer treatment.

Purpose of the Study:

  • To identify novel regulators of breast cancer stem cell formation.
  • To elucidate the molecular mechanisms underlying CSC regulation.
  • To explore potential therapeutic targets for breast cancer.

Main Methods:

  • Investigated the role of dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) in breast cancer.
  • Assessed the impact of DYRK2 downregulation on CSC traits in vitro and in vivo.
  • Analyzed the involvement of Krupple-like factor 4 (KLF4) and androgen receptor (AR) in the DYRK2 pathway.

Main Results:

  • DYRK2 acts as a novel negative regulator of breast cancer stem cell formation.
  • Downregulation of DYRK2 promotes CSC-like traits, tumorigenesis, and increases CSC proportion in human breast cancer tissues.
  • DYRK2 regulates KLF4 expression via AR-dependent transcriptional activity, mediating CSC phenotype.

Conclusions:

  • The DYRK2-AR-KLF4 signaling axis is a key mechanism regulating breast cancer stem cells.
  • Targeting this pathway presents a promising therapeutic strategy against breast cancer stem cells.
  • DYRK2's role as a tumor suppressor in breast cancer stem cell regulation is highlighted.

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

5.2K
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.8K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K